Safety and Efficacy of 70–150 μm and 100–300 μm Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma

Deipolyi, Amy R.; Öklü, Rahmi; Al-Ansari, Shehab; Zhu, Andrew X.; Goyal, Lipika; Ganguli, Suvranu

doi:10.1016/j.jvir.2014.12.020

Cited by 68 publications

(54 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There was no difference in 1 month imaging response. Patients receiving smaller beads were readmitted more often within 1 month, with 25% rate of hepatobiliary adverse events including ascites, gastrointestinal hemorrhage, biliary dilatation and cholecystitis which was significantly higher rate than the 9% hepatobiliary adverse events in larger beads group [48].…”

Section: Delivery Platformmentioning

confidence: 84%

Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?

et al. 2016

View full text Add to dashboard Cite

Conventional transarterial chemoembolization (c-TACE) was validated in 2002 for intermediate stage hepatocellular carcinoma (HCC). Recent improvements in overall survival after c-TACE in HCC is linked to both better patient selection, and improvement in treatment technologies: catheter, image guidance and new drug delivery platforms. Drug eluting beads (DEBs) demonstrated a benefit over c-TACE in pharmacokinetic studies; however, two randomized studies comparing c-TACE and DEB-TACE demonstrated no benefit of DEB-TACE in response rate or overall survival. Delivery platforms loaded with yttrium-90 deliver selective internal radiation therapy, which opens a new field of therapy for HCC. Future improvement in intra-arterial therapies will include resorbable loadable embolic material, new emulsion used for c-TACE and platforms releasing multikinase inhibitors.

show abstract

Section: Delivery Platformmentioning

confidence: 84%

Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Studies have investigated the ideal size of the microspheres for drug delivery in DEB-TACE. A recent study compared the safety and efficacy of 70-150 μm DEB to 100-300 μm DEBs [90] . A cohort of HCC patients who underwent TACE with two vials of 100-300 μm DEBs was compared to those treated with one vial of 70-150 μm DEBs followed by one vial of 100-300 μm DEBs.…”

Section: Intermediate Stage Hccmentioning

confidence: 99%

Locoregional treatment for hepatocellular carcinoma: The best is yet to come

Kalra

Gupta

Chawla

et al. 2015

WJR

View full text Add to dashboard Cite

“…Very recent studies have shown small microspheres (≤ 100 m) to be of particular benefit as they cause more distal embolization [26,[32][33][34]. More severe hepatic and biliary toxicity, however, has also been found for the microspheres compared to Lipiodol ® [35,36].…”

Section: Tace With Microspheresmentioning

confidence: 99%

Transarterial chemoembolization for hepatocellular carcinoma: An old method, now flavor of the day

Boulin

Delhom

Pierredon-Foulongne

et al. 2015

Diagnostic and Interventional Imaging

View full text Add to dashboard Cite

Transarterial chemoembolization (TACE) is the recommended treatment for patients suffering from intermediate, B stage, hepatocellular carcinoma. Despite an undisputed pharmacokinetic advantage, TACE with microspheres has not been shown to be superior in terms of survival compared to conventional TACE using Lipiodol(®). The best guarantee to reduce toxicity and maximize the efficacy of TACE is to strictly observe the contraindications for the procedure (Child-Pugh>B8, reduced portal flow, very large tumor, any technical contraindication and renal impairment), and rigorous application of the administration requirements for the Lipiodol(®) emulsion or loaded microspheres (assessment of hepatic vascularization investigating for accessory vascularization, injection methods). Tumor response should be assessed after four weeks by CT or MRI using the modified RECIST criteria.

show abstract

Safety and Efficacy of 70–150 μm and 100–300 μm Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma

Cited by 68 publications

References 17 publications

Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?

Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?

Locoregional treatment for hepatocellular carcinoma: The best is yet to come

Transarterial chemoembolization for hepatocellular carcinoma: An old method, now flavor of the day

Contact Info

Product

Resources

About